COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Profile

Loading content
 Madhusubramanian Muthukumar

Madhusubramanian Muthukumar

Research Fellow in Modelling for Health Economics and Public Health

 South Cloisters 

 

South Cloisters, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Madhusubramanian has a background in biotechnology and pursued masters in operational research and management science at Lancaster University. His interest in health economic modelling started with the dissertation work at Liverpool School of Tropical Medicine (LSTM), where he performed the discrete event simulation for modelling blood transfusion services in low- and middle-income countries. Over 6 years of experience across consulting and industry, he has led the development of economic evaluation of health care interventions including, but not limited to: cost effectiveness, budget impact and multi-criteria decision analysis (MCDA) models from conceptualisation to implementation across different disease areas such as Cervical dystonia, Asthma, Allergic rhinitis, Idiopathic pulmonary fibrosis, Schizophrenia and Bipolar mania.

In his current role as a Research Fellow in Modelling for Health Economics and Public health at PenTAG, Madhusubramanian undertakes the health technology assessment (HTA) of healthcare interventions, focusing especially on the critique of economic models for The National Institute for Health and Care Excellence (NICE).

Qualifications

  • Bachelor of Technology in Biotechnology (Hons.)
  • Master of Science in Operational Research and Management Science (Merit)

Research group links

Research

Research interests

  • Health economic modelling
  • Health Technology Assessment
  • Methods for economic evaluation of healthcare interventions
  • Discrete event simulation

Research projects

  • NICE STA: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy 
  • NICE HST: Givosiran for treating acute hepatic porphyria 

Publications

Key publications | Publications by category | Publications by year

Key publications


Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J (2017). Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. Clinicoecon Outcomes Res, 9, 211-229. Abstract.  Author URL.

Publications by category


Journal articles

Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Hasani I, Mtibaa M, Olivenstein R (2020). Cost-Effectiveness of Once-Daily Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma. Value in Health, 23, S723-S724.
Muthukumar M, Kozawa M, Alvares L, Milligan K, Igarashi A (2018). Cost-effectiveness analysis of omalizumab compared with standard of care for severe allergic asthma based on real world evidence in Japan. Value in Health, 21, S104-S105.
Corless S, Alvares L, Kumar P, Muthukumar M, Lesperance S, Katsaounou P (2018). Population health impact of omalizumab over 11 years of use in Ireland in moderate to severe allergic asthma. Value in Health, 21, S405-S405.
Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J (2017). Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. Clinicoecon Outcomes Res, 9, 211-229. Abstract.  Author URL.
Alvares L, Kumar P, Muthukumar M, Lesperance S, Katsaounou P (2017). Population Health Impact of Omalizumab over 15 Years of Experience in Moderate to Severe Allergic Asthma. Value in Health, 20(9), A652-A653.
Desai K, Muthukumar M, Abogunrin S, Harrower T, Dinet J, Gabriel S (2015). Abobotulinumtoxin a in the management of cervical dystonia in the United Kingdom: a cost-effectiveness analysis. Value in Health, 18(7), A757-A757.

Publications by year


2020

Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Hasani I, Mtibaa M, Olivenstein R (2020). Cost-Effectiveness of Once-Daily Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma. Value in Health, 23, S723-S724.

2018

Muthukumar M, Kozawa M, Alvares L, Milligan K, Igarashi A (2018). Cost-effectiveness analysis of omalizumab compared with standard of care for severe allergic asthma based on real world evidence in Japan. Value in Health, 21, S104-S105.
Corless S, Alvares L, Kumar P, Muthukumar M, Lesperance S, Katsaounou P (2018). Population health impact of omalizumab over 11 years of use in Ireland in moderate to severe allergic asthma. Value in Health, 21, S405-S405.

2017

Muthukumar M, Desai K, Abogunrin S, Harrower T, Gabriel S, Dinet J (2017). Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. Clinicoecon Outcomes Res, 9, 211-229. Abstract.  Author URL.
Alvares L, Kumar P, Muthukumar M, Lesperance S, Katsaounou P (2017). Population Health Impact of Omalizumab over 15 Years of Experience in Moderate to Severe Allergic Asthma. Value in Health, 20(9), A652-A653.

2015

Desai K, Muthukumar M, Abogunrin S, Harrower T, Dinet J, Gabriel S (2015). Abobotulinumtoxin a in the management of cervical dystonia in the United Kingdom: a cost-effectiveness analysis. Value in Health, 18(7), A757-A757.

M_Muthukumar Details from cache as at 2021-06-23 09:25:38

Refresh publications

External Engagement and Impact

Awards

  • Summer Undergraduate Research Program (SURP) Fellowship (2009), Dr. B.R. Ambedkar Centre for Biomedical Research (ACBR), University of Delhi, India.
  • Robinson scholar of the year (2012/13), Department of Management science, Lancaster University Management School (LUMS), Lancaster University, UK.

Teaching

Supervision / Group

Back | Edit Profile